Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy

Recruiting

Phase 3

Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy

Sponsor:

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Code:

NCT02262832

Conditions

Lipodystrophy

Diabetes

Hyperlipidemia

Eligibility Criteria

Sex: All

Age: 6 - 70+

Healthy Volunteers: Not accepted

Interventions

Metreleptin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-15. This information was provided to ClinicalTrials.gov by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) on 2025-02-27.